Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl sublingual - Orexo

Drug Profile

Fentanyl sublingual - Orexo

Alternative Names: Abstral; EN-3267; Fentanyl citrate sublingual tablets; Fentanyl transmucosal - Orexo; KW-2246; OX-20; Rapinyl

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orexo
  • Developer Galena Biopharma; Kyowa Kirin; Kyowa Kirin International; Paladin Labs
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 19 Jan 2017 Sentynl Therapeutics has been acquired by Zydus Cadila
  • 03 May 2016 Re-launched for Cancer pain by Sentnyl Therapeutics in USA (Sublingual)
  • 03 May 2016 The US label for sublingual fentanyl carries a black box warning related to the risk of respiratory depression, medication errors and abuse potential
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top